European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay

SAN DIEGO, Oct. 30, 2019 -- (Healthcare Sales & Marketing Network) -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA™ (gilteritinib) as a monotherapy for the treatment of adult patients with rel... Diagnostics, Oncology, Regulatory Invivoscribe, Astellas, XOSPATA, gilteritinib, LeukoStrat CDx FLT3

Source: HSMN NewsFeed - October 30, 2019 Category: Pharmaceuticals Source Type: news